Clinical trial is a type of research that studies tests and treatments and evaluates their effects on human health. People volunteer to take part in clinical trials to test medical interventions including drugs, cells and other biological products, surgical procedures, radiological procedures, devices, behavioral treatments and preventive care. A clinical trial is often used to find out if a new treatment has more effectiveness and / or fewer side effects than the standard treatment.
Clinical trials are carefully designed, reviewed and need to be approved before they can start. There are 4 clinical phases:
.jpg)
With the aim of accomplishing fully drug development process, Nanogen conducts from drug molecular research to preclinicals and clinical trials in order to ensure that we deliver the best products to consumers.
At Nanogen, all clinical trials are run according to the Principles of Good Clinical Practice (GCP) of ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use) or GCP of WHO (World Health Organization). Additionally, they must be approved by National Regulatory Authorities and Ethics Committees.
During the phases of trials, Nanogen takes evaluation of the benefit-risk portfolio of products. If the risks outweight patients’ benefits, Nanogen will amend the protocol or terminate the trial. Furthermore, we have taken several important steps to ensure that clinical trial results reach the public in a timely and objective manner.
How does Nanogen conduct clinical trials?
With the aim of accomplishing fully drug development process, Nanogen conducts from drug molecular research to preclinicals and clinical trials in order to ensure that we deliver the best products to consumers.
At Nanogen, all clinical trials are run according to the Principles of Good Clinical Practice (GCP) of ICH (International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human use) or GCP of WHO (World Health Organization). Additionally, they must be approved by National Regulatory Authorities and Ethics Committees.
During the phases of trials, Nanogen takes evaluation of the benefit-risk portfolio of products. If the risks outweight patients’ benefits, Nanogen will amend the protocol or terminate the trial. Furthermore, we have taken several important steps to ensure that clinical trial results reach the public in a timely and objective manner.
